2298-49-9

Usage

Type of compound

Atypical antidepressant and smoking cessation aid

Function

Increases levels of dopamine and norepinephrine in the brain

Uses

Treatment of major depressive disorder, seasonal affective disorder, and as a smoking cessation aid

Off-label uses

Treatment of attention deficit hyperactivity disorder (ADHD) and bipolar disorder

Side effects

Can have potentially serious side effects and interactions with other medications

Importance

Versatile and important chemical compound in the realm of mental health and smoking cessation.

Upstream product

• 50-00-0 formaldehyd 
• 7732-18-5 water 
• 98-86-2 acetophenone 
• 64-17-5 ethanol 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 123612-89-5 1-Methyl-4,5-diphenyl-2,3,6,7-tetrahydro-1H-azepine 
• 57624-47-2 3-(4-bromophenylamino)-1-phenylpropan-1-one 
• 3506-40-9 β-(p-hydroxyphenylamino)propiophenone 
• 95624-64-9 N-cyclohxyl-3-benzoyl-4-hydroxy-4-phenylpiperidine 
• 58153-99-4 3-((4-chlorophenyl)amino)-1-phenylpropan-1-one 
• 4173-65-3 3-[(4-methoxyphenyl)amino]-1-phenylpropan-1-one 
• 1120358-72-6 N-[2-(3,4-dimethoxyphenyl)ethyl]-3-benzoyl-4-hydroxy-4-phenylpiperidine 
• 1120358-73-7 2,3,6,7-tetrahydro-1-(β-benzoylethyl)-5-phenyl-1H-1,4-diazepine 
• 2983-48-4 1-phenyl-3-(phenylamino)propan-1-one 
• 2538-52-5 1,3-diphenyl-4,5-dihydro-1H-pyrazole 
• 14554-17-7 N-benzyl-3-benzoyl-4-hydroxy-4-phenylpiperidine 
• 3874-93-9 N,N'-bis(β-benzoylethyl)-p-phenylenediamine 
• 1228302-01-9 C₁₈H₁₂N₂S 
• 1702-14-3 ethyl 2-methyl-6-phenylnicotinate 

Relevant academic research and scientific papers

Effect of some bis mannich bases and corresponding piperidinols on DNA topoisomerase I

Some acetophenone (CAS 98-86-2) derived bis Mannich bases, bis-(3-aryl-3-oxo-propyl)-methylamine hydrochlorides (B1-B5) and representative piperidinols, 4-aryl-3-arylcarbonyl-1-methyl-4-piperidinol hydrochlorides (C1, C2 and C5), which are the structural isomers of B1, B2 and B5, were synthesized and their effects on DNA topoisomerase I were tested. Aryl part was phenyl in B1 and C1, p-methyl-phenyl in B2 and C2, p-methoxyphenyl in B3, p-chlorophenyl in B4, and 2-thienyl in B5 and C5. The compounds' chemical structures were confirmed by UV, IR, 1H NMR, 13C NMR, ESI-MS spectra. The purity levels of the compounds were determined by elemental analysis. Among the compounds, B1-B5 and C5 were found to inhibit DNA topo isomerase I at varying degrees. The compounds B1-B5 and C5 manifested an average of 46%, 20%, 40%, 22%, 24% and 22% inhibition on topoisomerase I, respectively, suggesting that the cytotoxic actions of the compounds may be linked to DNA topoisomerase I inhibition. There was a significant negative correlation between the LC 50 values reported and topoisomerase I inhibition among the compounds studied. The topoisomerase inhibiting effects of the compounds of the B series may be attributed to the linear structures of the compounds and the possible formation of the hydrogen bonds with the DNA nucleotides. Among the compounds studied, the most potent topoisomerase I inhibiting compounds B1 (46%) and B3 (40%) may serve as model compounds to develop new more potent topoisomerase inhibitors in future studies. ECV Editio Cantor Verlag.

Synthesis and evaluation of anticonvulsant activities of some bis Mannich bases and corresponding piperidinols

Some acetophenone derived bis Mannich bases (B1-B5) and piperidinols (C1, C4), which are the structural isomers of B1 and B4, and also quaternary piperidine derivative C6 were synthesized and studied for anticonvulsant activity. Of the compounds, C6 was reported for the first time. Chemical structures of the compounds were confirmed by UV, IR, 1H-NMR, 13C-NMR, mass spectra and elemental analysis. Their anticonvulsant activities were determined by maximal electroshock (MES), subcutaneous metrazol (scMet) tests and rotarod test for neurological deficits. According to the activity studies, B2, B4, C1 and C4 derivatives were found to be protective against MES at 30 mg/kg and above. B1, B2, B3, B4, C4 and C6 derivatives were found to be protective against scMet, at different dose levels ranging from 30 to 300 mg/kg. Since no neurotoxicity was detected for the compounds B4 and C4, they seem to be candidate compounds for further synthesis and in vivo studies for their potential anticonvulsant activity.